Morin G, Zerbib L, Kaltenbach S, Fraissenon A, E, Balducci E, Asnafi V and Canaud G. PIK3CA-related disorders: From Disease Mechanism to Evidence-Based Treatments. Annu Rev Genomics Hum Genet. 2024; doi: 10.1146/annurev-genom-121222-114518.

Yamaguchi J and Canaud G. mTOR Signaling and Human Physiology Relevant to Kidney Disease. J Am Soc Nephrol . 2024; doi: 10.1681/ASN.0000000000000450.

Fraissenon A, Bayard C, Morin G, Benichi S, Hoguin C, Protic S, Zerbib L, Ladraa S, Firpion M, Blauwblomme T, Naggara O, Duruisseaux M, Delous M, Boitel C, Bringuier PP, Payen L, Legendre C, Kaltenbach S, Balducci E, Villarese P, Asnafi V, Bisdorff A, Guibaud L, Canaud G. Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation. N Engl J Med. 2024; Jul 25;391(4):334-342. doi: 10.1056/NEJMoa2309160. PMID: 39018528.

Guillon E., Bacar H., Sasaki T., Mourikis P., and Ruggiero F. Defining a Muscle Stem Cell matrisome signature: from transcriptome data to extracellular matrix niche topology. Stem Cell Reports. 2024; doi: 10.1101/2024.07.10.602878.

Zerbib L, Ladraa S, Fraissenon A, Bayard C, Firpion M, Venot Q, Protic S, Hoguin C, Thomas A, Fraitag S, Duong JP, Kaltenbach S, Balducci E, Lefevre C, Villarese P, Asnafi V, Broissand C, Goudin N, Nemazanyy I, Autret G, Tavitian B, Legendre C, Arzouk N, Minard-Colin V, Chopinet C, Dussiot M, Adams DM, Mirault T, Guibaud L, Isenring P, Canaud G. Targeted therapy for capillary-venous malformations. Signal Transduct Target Ther. 2024; Jun 17;9(1):146. doi: 10.1038/s41392-024-01862-9. PMID: 38880808; PMCID: PMC11180659.

Xiang Y, Mata-Garrido J, Fu Y, Desterke C, Batsché E, Hamaï A, Sedlik C, Sereme Y, Skurnik D, Jalil A, Onifarasoaniaina R, Frapy E, Beche JC, Alao R, Piaggio E, Arbibe L, Chang Y. CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity. EMBO Mol Med.. 2024; 16(6):1404-1426 Epub 2024 Apr 29.. doi: 10.1038/s44321-024-00066-6.

Xiang Y, Mata-Garrido J, Fu Y, Desterke C, Batsché E, Hamaï A, Sedlik C, Sereme Y, Skurnik D, Jalil A, Onifarasoaniaina R, Frapy E, Beche JC, Alao R, Piaggio E, Arbibe L, Chang Y. CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity. EMBO Mol Med. 2024; Jun;16(6):1404-1426. doi: 10.1038/s44321-024-00066-6. PMID: 38684864; PMCID: PMC11178889.

Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Rigal-Huguet F, Ducassou S, Lheritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre EA, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V. NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patients. Blood. 2024; Jun 7:blood.2023023754. Epub ahead of print. doi: 10.1182/blood.2023023754. PMID: 38848537.

Yamaguchi J, Isnard P, Robil N, de la Grange P, Hoguin C, Schmitt A, Hummel A, Mégret J, Goudin N, Luka M, Ménager MM, Masson C, Zarhrate M, Bôle-Feysot C, Janiszewska M, Polyak K, Dairou J, Baldassari S, Baulac S, Broissand C, Legendre C, Terzi F, Canaud G. PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis. J Clin Invest. 2024; Jun 6:e176402. Epub ahead of print. doi: 10.1172/JCI176402. PMID: 38842935.

Bardin E, Dietrich C, Attailia M, Ferroni A, Jamet A, Lezmi G, Sermet-Gaudelus I, Leite-de-Moraes M. Restored Cytokine-Producing Capacities of Mucosal-Associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor. Am J Respir Crit Care Med. 2024; May 17. Epub ahead of print. doi: 10.1164/rccm.202401-0201LE. PMID: 38760016.